Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Serge Jabbour. (2014) Comment and response to: dapagliflozin – do we need it registered for type 2 diabetes?. Expert Opinion on Pharmacotherapy 15:18, pages 2751-2753.
Read now
Read now
Sheila A Doggrell & Rinku Tuli. (2014) Dapagliflozin – do we need it registered for type 2 diabetes?. Expert Opinion on Pharmacotherapy 15:11, pages 1631-1635.
Read now
Read now
Sheila A Doggrell & Kerry McIntyre. (2014) Canagliflozin – something new for type 2 diabetes, but is it safe and efficacious?. Expert Opinion on Pharmacotherapy 15:3, pages 437-441.
Read now
Read now
Nikolaos Papanas, Niki Katsiki, Apostolos I Hatzitolios & Efstratios Maltezos. (2011) Pioglitazone: a valuable component of combination therapy for type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 12:10, pages 1457-1461.
Read now
Read now
Sundy Ny Yang, Narin Osman, Micah Burch & Peter Little. (2009) Factors affecting proteoglycan synthesis and structure that modify the interaction with lipoproteins. Clinical Lipidology 4:4, pages 479-494.
Read now
Read now
Articles from other publishers (15)
Rong‐Xing Liu, Yan Ma, Xue‐Lian Hu, Yun‐Peng Liao, Xiang‐Nan Hu, Bai‐Cheng He & Wen‐Juan Sun. (2018) Pioglitazone/metformin adduct regulates insulin secretion and inhibits high glucose‐induced apoptosis via p21‐p53‐MDM2 signaling in INS‐1 cells. Journal of Cellular Biochemistry 119:7, pages 5449-5459.
Crossref
Crossref
Harinda Rajapaksha, Harpreet Bhatia, Kate Wegener, Nikolai Petrovsky & John B. Bruning. (2017) X-ray crystal structure of rivoglitazone bound to PPARγ and PPAR subtype selectivity of TZDs. Biochimica et Biophysica Acta (BBA) - General Subjects 1861:8, pages 1981-1991.
Crossref
Crossref
Mohit Mazumder, Prija Ponnan, Umashankar Das, Samudrala Gourinath, Haseeb Ahmad Khan, Jian Yang & Meena Kishore Sakharkar. (2017)
Investigations on Binding Pattern of Kinase Inhibitors with PPAR
γ
: Molecular Docking, Molecular Dynamic Simulations, and Free Energy Calculation Studies
. PPAR Research 2017, pages 1-11.
Crossref
Crossref
Maryam Khavandi, Francisco Duarte, Henry N. Ginsberg & Gissette Reyes-Soffer. (2017) Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes. Current Cardiology Reports 19:1.
Crossref
Crossref
Michael J Kraakman, Dragana Dragoljevic, Helene L Kammoun & Andrew J Murphy. (2016) Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritis. Clinical & Translational Immunology 5:5, pages e84.
Crossref
Crossref
Laura M. van Marrewijk, Steven W. Polyak, Marcel Hijnen, Dana Kuruvilla, Mi Ra Chang, Youseung Shin, Theodore M. Kamenecka, Patrick R. Griffin & John B. Bruning. (2015) SR2067 Reveals a Unique Kinetic and Structural Signature for PPARγ Partial Agonism. ACS Chemical Biology 11:1, pages 273-283.
Crossref
Crossref
Xu‐Hong Yang, Peng Li, Ya‐Ling Yin, Jiang‐Hua Tu, Wen Dai, Li‐Ying Liu & Shuang‐Xi Wang. (2015)
Rosiglitazone
via
PPAR
γ‐dependent suppression of oxidative stress attenuates endothelial dysfunction in rats fed homocysteine thiolactone
. Journal of Cellular and Molecular Medicine 19:4, pages 826-835.
Crossref
Crossref
Matthew L. TrippGary DarlandVeera Reddy KondaLinda M. PaciorettyJyh-Lurn ChangJeffrey S. BlandJohn G. Babish. (2012)
Optimized mixture of hops rho iso-alpha acids-rich extract and acacia proanthocyanidins-rich extract reduces insulin resistance in 3T3-L1 adipocytes and improves glucose and insulin control in
db/db
mice
. Nutrition Research and Practice 6:5, pages 405.
Crossref
Crossref
Anatol Kontush & M. John Chapman. 2011. High‐Density Lipoproteins. High‐Density Lipoproteins
423
523
.
Katerina K Naka, Katerina Papathanassiou, Aris Bechlioulis, Konstantinos Pappas, Nikolaos Kazakos, Chryssanthi Kanioglou, Michail I Papafaklis, Aggeliki Kostoula, Patra Vezyraki, Demetrios Makriyiannis, Agathocles Tsatsoulis & Lampros K Michalis. (2011) Rosiglitazone improves endothelial function in patients with type 2 diabetes treated with insulin. Diabetes and Vascular Disease Research 8:3, pages 195-201.
Crossref
Crossref
Torbjörn Lindström, Stergios Kechagias, Martin Carlsson & Fredrik H. Nystrom. (2012) Transient Increase in HDL‐Cholesterol During Weight Gain by Hyperalimentation in Healthy Subjects. Obesity 19:4, pages 812-817.
Crossref
Crossref
Sheng-Hwu Hsieh, Kuang-Chung Shih, Chien-Wen Chou & Chih-Hsun Chu. (2010) Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas. Acta Diabetologica 48:1, pages 71-77.
Crossref
Crossref
Nikolaos P.E. Kadoglou, Fotios Iliadis, Nikolaos Sailer, Zoi Athanasiadou, Ioulia Vitta, Alikistis Kapelouzou, Panayotis E. Karayannacos, Christos D. Liapis, Miltiadis Alevizos, Nikoletta Angelopoulou & Ioannis S. Vrabas. (2010) Exercise training ameliorates the effects of rosiglitazone on traditional and novel cardiovascular risk factors in patients with type 2 diabetes mellitus. Metabolism 59:4, pages 599-607.
Crossref
Crossref
Jussi Sutinen. (2009) The Effects of Thiazolidinediones on Metabolic Complications and Lipodystrophy in HIV-Infected Patients. PPAR Research 2009, pages 1-15.
Crossref
Crossref
Monika Mueller & Alois Jungbauer. (2008) Red clover extract. Menopause 15:6, pages 1120-1131.
Crossref
Crossref